The RTS,S malaria vaccine candidate is the most clinically advanced to date globally. It became the first vaccine candidate to show in clinical trials that it can help protect young children (in 2004) and infants (in 2007) living in malaria-endemic areas against clinical disease and infection caused by Plasmodium (P.) falciparum, the most deadly species of the malaria parasite. Like vaccines generally, RTS,S aims to trigger the body’s own immune system to defend against disease, in this case, malaria. Specifically, RTS,S is designed to prevent the malaria parasite from infecting, maturing, and multiplying in the liver, after which the parasite would normally re-enter the bloodstream and infect red blood cells, leading to disease symptoms.
24 Apr 2017